Skip to main content

Advertisement

SpringerLink
Log in

Status of hyaluronan supplementation therapy in osteoarthritis

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Hyaluronans are polysaccharide molecules that occur naturally in synovial fluid; they help to create a viscous environment, cushion joints, and maintain normal function. The American College of Rheumatology recommends intraarticular injection of hyaluronans, which are available as several distinct therapeutic products, as an alternative to oral analgesics or nonsteroidal anti-inflammatory drugs for the symptomatic treatment of pain associated with osteoarthritis of the knee. A large body of literature supports the clinical efficacy and safety of this therapeutic class for this indication, although there are differences between the marketed products and they should be evaluated independently. Preliminary work investigating the use of hyaluronans for osteoarthritis in joints other than the knee has also produced promising results. There is growing evidence that hyaluronans, the biology of which is complex, may also have structure-modifying activity. Thus, compared with currently approved nonoperative therapies for osteoarthritis, hyaluronans may also have beneficial effects on the disease process in osteoarthritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Abatangelo G, O’Regan M: Hyaluronan: biological role and function in articular joints. Eur J Rheum Inflamm 1995, 15:9–16.

    Google Scholar 

  2. Hiscock DRR, Caterson B, Flannery CR: Expression of hyaluronan synthases in articular cartilage. Osteoarthritis Cartilage 2000, 8:120–126.

    Article  PubMed  CAS  Google Scholar 

  3. AP, McDonald JA: Spicer Eukaryotic hyaluronan synthases [Glycoforum 2000]. Available at: http://glycoforum.gr.jp/science/ hyaluronan/HA07/HA07E.html. Accessed June 20, 2002.

  4. Hardingham TE: Cartilage: Aggrecan-link protein-hyaluronan aggregates [Glycoforum]. Available at: http://www.glycoforum. gr.jp/science/hyaluronan/HA05/HA05E.html. Accessed on June 20, 2002.

  5. Nishida Y, D’Souza AL, Thonar EJ-MA, Knudson W: Stimulation of hyaluronan metabolism by interleukin-1a in human articular cartilage. Arthritis Rheum 2000, 43:1315–1326.

    Article  PubMed  CAS  Google Scholar 

  6. Takahashi K, Goomer RS, Harwood F, et al.: The effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin- 1b), and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. Osteoarthritis Cartilage 1999, 7:182–190.

    Article  PubMed  CAS  Google Scholar 

  7. Jacobson A, Brinck J, Briskin MJ, et al.: Expression of human hyaluronan synthases in response to external stimuli. Biochem J 2000, 348:29–35.

    Article  PubMed  CAS  Google Scholar 

  8. Dahl LB, Dahl IMS, Engstrom A, Granath K: Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis 1985, 44:817–822.

    PubMed  CAS  Google Scholar 

  9. Balazs EA, Denlinger JL: Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl 1993, 39:3–9.

    PubMed  CAS  Google Scholar 

  10. Synvisc [prescribing information]. Philadelphia, PA: Wyeth- Ayerst; 2000.

  11. Supartz [prescribing information]. Tokyo, Japan: Seikagaku Corp; 2001.

  12. Hyalgan [prescribing information]. New York, NY: Sanofi Pharmaceuticals, Inc; 2001.

  13. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines: Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000, 43:1905–1915. The most recent guidelines for the treatment of OA issued by the American College of Rheumatology. Intra-articular HA therapy has been recommended for the first time as an alternative to oral analgesics or NSAIDs.

    Article  Google Scholar 

  14. Balazs EA, Leschiner A, Leschiner A, et al.: Hylan preparation and method of recovery thereof from animal tissues. US Patent 5,099,013. November 16, 1990.

  15. Altman RD, Moskowitz R: Intraarticular sodium hyaluronate in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. J Rheumatol 1998, 25:2203–2212. An important multicenter, randomized, controlled trial involving 456 patients that demonstrated the safety and efficacy of at least 26 weeks’ duration of sodium hyaluronate.

    PubMed  CAS  Google Scholar 

  16. Huskisson EC, Donnelly S: Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology 1999, 38:602–607.

    Article  PubMed  CAS  Google Scholar 

  17. Henderson EB, Smith EC, Pegley F, Blake DR: Intra-articular injections of 750 kD hyaluronan in the treatment of osteoarthritis: a randomized single center double-blind placebo-controlled trial of 91 patients demonstrating lack of efficacy. Ann Rheum Dis 1994, 53:529–534.

    PubMed  CAS  Google Scholar 

  18. Carrabba M, Paresce E, Angelini M, et al.: The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion. Eur J Rheumatol Inflamm 1995, 15:25–31.

    Google Scholar 

  19. Bragantini A, Cassini M, DeBastiani G, Perbellini A: Controlled single-blind trial of intrarticularly injected hyaluronic acid in osteoarthritis of the knee. Clin Trial J 1987, 24:333–341.

    Google Scholar 

  20. Dougados M, Nguyen M, Listrat V, Amor B: High molecular weight sodium hyaluronate in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthritis Cartilage 1993, 1:97–103.

    Article  PubMed  CAS  Google Scholar 

  21. Grecomoro G, Martorana U, DiMarco C: Intra-articular treatment with sodium hyaluronate in gonarthrosis: a controlled clinical trail versus placebo. Pharmacotherapeutica 1987, 5:137–141.

    CAS  Google Scholar 

  22. Kotz R, Kolarz G: Intra-articular hyaluronic acid: duration of effect and results of repeated treatment cycles. Am J Orthop 1999, 28(suppl):5–7.

    PubMed  CAS  Google Scholar 

  23. Scali JJ: Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: a long-term study. Eur J Rheumatol Inflamm 1995, 15:57–62.

    Google Scholar 

  24. Wobig M, Dickhut A, Maier R, Vetter G: Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 1998, 20:410–423. A pivotal, randomized, controlled trial involving 110 patients that demonstrated the safety and efficacy of at least 12-weeks’ duration of hylan G-F 20. A 26-week telephone survey was also supportive of efficacy at that time point.

    Article  PubMed  CAS  Google Scholar 

  25. Scale D, Wobig M, Wolpert W: Viscosupplementation of osteoarthritis knees with hylan: a treatment schedule study. Curr Ther Res 1994, 55:220–232.

    Article  Google Scholar 

  26. Wobig M, Bach G, Beks P, et al.: The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecularweight hyaluronan. Clin Ther 1999, 21:1549–1562.

    Article  PubMed  CAS  Google Scholar 

  27. Synvisc Premarket Approval Application: Summary of Safety and Effectiveness Data. Available at: http://www.fda.gov/cdrh/ pdf/p940015.pdf. Accessed June 20, 2000.

  28. Puhl W, Bernau A, Greiling H, et al.: Intra-articular sodium hyaluronate in osteoarthritis of the knee: a multicenter, double-blind study. Osteoarthritis Cartilage 1993, 1:233–241. The only large well-controlled trial evaluating sodium hyaluronate that supported its efficacy compared with vehicle control treatments.

    Article  PubMed  CAS  Google Scholar 

  29. Lohmander LS, Dalén N, Englund G, et al.: Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomized, double blind, placebo controlled multicenter trial. Ann Rheum Dis 2003, 55:424–431.

    Article  Google Scholar 

  30. Dahlberg L, Lohmander LS, Ryd L: Intra-articular injections of hyaluronan in patients with cartilage abnormalities and knee pain. Arthritis Rheum 1994, 37:521–528.

    Article  PubMed  CAS  Google Scholar 

  31. Sakamoto T, Mizuno S, Miyazaki K, et al.: Biological fate of sodium hyaluronate (SPH) (1) Studies on distribution, metabolism and excretion of 14C-SPH in rabbits after intraarticular administration. Pharmacometrics 1984, 28:375–387.

    CAS  Google Scholar 

  32. Synvisc [prescribing information]. Auckland, NZ: Bayer New Zealand Limited; 1999.

  33. Altman R, Brandt K, Hochberg M, Moskowitz R: Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Osteoarthritis Cartilage 2003, 4:217–243. These recommendations for the design and conduct of clinical trials involving patients with OA provide a thorough explanation of the requirements for establishing structure- or disease-modifying activity of agents for the treatment of OA. It is emphasized that the primary outcome variables should relate to joint morphology using imaging procedures rather than any outcome that may be influenced by factors unrelated to disease progression, such as improved function or delay in knee surgery.

    Article  Google Scholar 

  34. Punzi L: The complexity of the mechanisms of action of hyaluronan in joint diseases. Clin Exp Rheumatol 2001, 19:242–246.

    PubMed  CAS  Google Scholar 

  35. Ghosh P, Guidolin D: Potential mechanism of action of intraarticular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent. Sem Arthr Rheum 2002, In press. A well written and thorough review of the biochemical activities of HA that may contribute to their mechanisms of action in the treatment of osteoarthritis. The authors place special emphasis on the potential role of HA molecular weight in HA action.

  36. Kikuchi T, Yamada H, Shimmei M: Effect of high molecular weight hyaluronan on cartilage degradation in a rabbit model of osteoarthritis. Osteoarthritis Cartilage 2003, 4:99–110.

    Article  Google Scholar 

  37. Armstrong S, Read R, Ghosh P: The effects of intra-articular hyaluronan on cartilage and subchondral bone changes in an ovine model of early osteoarthritis. J Rheumatol 1994, 21:680–688.

    PubMed  CAS  Google Scholar 

  38. Yoshioka M, Shimizu C, Harwood FL, et al.: The effects of hyaluronan during the development of osteoarthritis. Osteoarthritis Cartilage 1997, 5:251–260.

    Article  PubMed  CAS  Google Scholar 

  39. Shimazu C, Yoshioka M, Coutts RD, et al.: Long-term effects of hyaluronan on experimental osteoarthritis in the rabbit knee. Osteoarthritis Cartilage 1998, 6:1–9.

    Article  Google Scholar 

  40. Marshall KW: The current status of hylan therapy for the treatment of osteoarthritis. Today’s Therapeutic Trends 1997, 15:99–108.

    Google Scholar 

  41. Schiavinato A, Lini E, Guidolin D, et al.: Intraarticular sodium hyaluronate injections the Pond-Nuki experimental model of osteoarthritis in dogs, II: morphological findings. Clin Orthop 1989, 241:286–299.

    PubMed  Google Scholar 

  42. Toyoguichi T, Morihara T, Yamada K, et al.: Long term effect of multiple courses of intraarticular injections of sodium hyaluronan during the development of osteoarthritis. Osteoarthritis Cartilage 2001, 9:S26.

    Google Scholar 

  43. Listrat V, Ayral X, Patarnello F, et al.: Arthroscopic evaluation of potential structure modifying activity of hyaluronan in osteoarthritis of the knee. Osteoarthritis Cartilage 1997, 5:153–160.

    Article  PubMed  CAS  Google Scholar 

  44. Frizziero L, Govoni E, Bacchini P: Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: clinical and morphological study. Clin Exp Rheumatol 1998, 16:441–449.

    PubMed  CAS  Google Scholar 

  45. Ronchetti IP, Guerra D, Taparelli F, et al.: Morphological analysis of knee synovial membrane biopsies from a randomized controlled clinical study comparing the effects of sodium hyaluronate and methylprednisolone acetate in osteoarthritis. Rheumatology 2001, 40:158–169.

    Article  CAS  Google Scholar 

  46. Guidolin DD, Ronchetti IP, Lini E, et al.: Morphological analysis of articular cartilage biopsies from a randomized, clinical study comparing the effects of 500-730 kDa sodium hyaluronate and methylprednisolone acetate on primary osteoarthritis of the knee. Osteoarthritis Cartilage 2001, 9:371–381.

    Article  PubMed  CAS  Google Scholar 

  47. Jubb RW, Piva S, Beinat I, et al.: Structure modifying study of hyaluronan (500-730 Kda) on osteoarthritis of the knee. Abstract presented at the 65th Annual American College of Rheumatology National Scientific Meeting; San Francisco, CA; November 10–15, 2001.

  48. Luzar MJ, Altawil B: Pseudogout following intraarticular injection of sodium hyaluronate. Arthritis Rheum 1998, 41:939–941.

    Article  PubMed  CAS  Google Scholar 

  49. Disla E, Infante R, Fahmy A, et al.: Recurrent acute calcium pyrophosphate dihydrate arthritis following intraarticular hyaluronate injection. Arthritis Rheum 1999, 42:1302–1303.

    Article  PubMed  CAS  Google Scholar 

  50. Hammesfahr R, Knopf AB, Stitik T: Safety of intra-articular hyaluronates for pain associated with osteoarthritis of the knee. Am J Orthop 2003, In press.

  51. Bucher W, Otto T, Hamburger MI: Possible mechanism for product-specific severe adverse reactions? - differentiation of hyaluronate products by qualitative differences in their immunogenicity in rabbits. Arthritis Rheum 2003, In press.

  52. Randal G: Immunogenicity of hyaluronic acid products: comparison of Synvisc and Artz in guinea pigs. Paper presented at the International Cartilage Repair Society 4th Symposium; Toronto, Canada. June 15–18, 2002;

  53. Yamamoto R, Namiki O, Iwata H, et al.: Randomized comparative study of sodium hyaluronate (SPH) on periarthritis of the shoulder. Jpn J Clin Pharmacol Ther 1988, 19:717–733.

    Google Scholar 

  54. Leardini G, Perbellini A, Franceschini M, Mattara L: Intraarticular injections of hyaluronic acid in the treatment of painful shoulder. Clin Ther 1988, 10:521–526.

    PubMed  CAS  Google Scholar 

  55. Itokazu M, Matsunaga T: Clinical evaluation of high-molecularweight sodium hyaluronate for the treatment of patients with periarthritis of the shoulder. Clin Ther 1995, 17:946–955.

    Article  PubMed  CAS  Google Scholar 

  56. Bragantini A, Molinaroli F: A pilot clinical evaluation of the treatment of hip osteoarthritis with hyaluronic acid. Curr Ther Res 1994, 55:319–330.

    Article  Google Scholar 

  57. Hanson EC: Sodium hyaluronate-application in a community practice. Am J Orthop 1999, 28:11–12.

    PubMed  CAS  Google Scholar 

  58. Ueno Y, Kuramoto K, Konno N, et al.: Investigation result of use after launch of ARTZ and ARTZ dispo. Jpn Pharmacol Ther 1995, 23:2151–2170.

    Google Scholar 

  59. Adams ME, Atkinson MA, Lussier AJ, et al.: The role of viscosupplementation with hylan G-F 20 in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with nonsteroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage 1995, 3:213–226.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Rheumatology and Immunology, University of Miami School of Medicine, PO Box 106960, 33101, Miami, FL, USA

    Roy D. Altman MD

Authors
  1. Roy D. Altman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Altman, R.D. Status of hyaluronan supplementation therapy in osteoarthritis. Curr Rheumatol Rep 5, 7–14 (2003). https://doi.org/10.1007/s11926-003-0077-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-003-0077-6

Keywords

Search

Navigation